再生元製藥公司 REGN 深 滬
等待開盤 09-25 09:30:00 美东时间
796.02
-5.800
-0.72%
華盛通- 最 高807.205
- 今 開801.59
- 成交量 58.49万股
- 最 低 789.39
- 昨 收 801.82
- 總市值 819.54亿
- 52周最高 859.34
- 市盈率 靜 19.19
- 換手率 0.57%
- 52周最低 537.30
- 委 比 88.71%
- 總股本 1.03亿
- 歷史最高 1204.8599
- 量 比 0.56
- 振 幅 2.22%
- 歷史最低 36.49
- 每 手 1
- 風險率 76.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Regeneron’s ROXI-EVEREST Trial Puts a New Stroke Drug in the Spotlight
Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical...
09-17 00:30
DexCom expands CFO’s role to COO
DexCom (DXCM) promoted Jereme Sylvain to chief operating officer while he continues serving as chief financial officer. Sylvain joined DexCom in 2018 and has served as CFO since 2021. More on DexCom D...
09-15 04:41
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920
HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.
09-10 21:38
内部人交易｜再生元制药披露一笔股票减持，金额约96.97万美元
美股上市公司再生元制药（REGN）披露一笔内部人股票交易。文件显示，公司内部人McCourt (Marion E)（Officer）2026-09-03减持公司...
09-05 07:01
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 17.79%. Currently, Regeneron Pharmaceuticals has a market capitalization of $86.70 billion. Buying $1000 In REGN: If an investor had bought...
09-03 00:45
Notable healthcare headlines for the week: Veeva Systems, Boston Scientific in focus
Wall Street ended Friday's session modestly lower as traders digested Federal Reserve Chair Kevin Warsh's speech at the Jackson Hole Symposium. The S&P 500 slipped 0.25%, the Dow was almost flat, and ...
08-30 21:05
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
CytomX Therapeutics announced that the FDA has granted Fast Track Designation to Varseta-M for the treatment of relapsed/refractory metastatic colorectal cancer. Varseta-M is a first-in-class antibody drug conjugate targeting EpCAM with a topoisomerase-1 inhibitor payload. The company plans to initiate a potential registrational study for Varseta-M monotherapy in R/R mCRC in the first half of 2027. Fast Track Designation aims to expedite developm...
08-27 12:00
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 19.2%. Currently, Regeneron Pharmaceuticals has a market capitalization of $85.30 billion. Buying $100 In REGN: If an investor had bought $...
08-25 07:45
